Literature DB >> 30777657

Intracerebral haemorrhage during alemtuzumab administration.

Christina J Azevedo1, Christen Kutz2, Amy Dix3, Aaron Boster4, Nerses Sanossian5, Jeffrey Kaplan3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30777657     DOI： 10.1016/S1474-4422(19)30076-6

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  14 in total

Review 1.  Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis.

Authors:  Sadia Nosher; Sehrish Fuad; Nupur Mishra; Zaid A Alrashid; Bindu Rathod; Devyani Mohan; Deepak M Basavanagowda; Arveen Kaur; Stacey E Heindl
Journal:  Cureus       Date:  2021-02-09

Review 2.  Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis.

Authors:  Gabrielle Macaron; Jenny Feng; Manikum Moodley; Mary Rensel
Journal:  Curr Treat Options Neurol       Date:  2019-09-27       Impact factor: 3.972

Review 3.  An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma.

Authors:  Faruque Ghanchi; Rupert Bourne; Susan M Downes; Richard Gale; Christina Rennie; Ian Tapply; Sobha Sivaprasad
Journal:  Eye (Lond)       Date:  2022-01-01       Impact factor: 4.456

Review 4.  The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis.

Authors:  Simona Rolla; Alessandro Maglione; Stefania Federica De Mercanti; Marinella Clerico
Journal:  Cells       Date:  2020-06-03       Impact factor: 6.600

5.  Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.

Authors:  Tjalf Ziemssen; Ann D Bass; Regina Berkovich; Giancarlo Comi; Sara Eichau; Jeremy Hobart; Samuel F Hunter; Christopher LaGanke; Volker Limmroth; Daniel Pelletier; Carlo Pozzilli; Sven Schippling; Livia Sousa; Anthony Traboulsee; Bernard M J Uitdehaag; Bart Van Wijmeersch; Zia Choudhry; Nadia Daizadeh; Barry A Singer
Journal:  CNS Drugs       Date:  2020-09       Impact factor: 5.749

Review 6.  Immunological Aspects of Approved MS Therapeutics.

Authors:  Paulus S Rommer; Ron Milo; May H Han; Sammita Satyanarayan; Johann Sellner; Larissa Hauer; Zsolt Illes; Clemens Warnke; Sarah Laurent; Martin S Weber; Yinan Zhang; Olaf Stuve
Journal:  Front Immunol       Date:  2019-07-11       Impact factor: 7.561

Review 7.  Nanomodulation of Macrophages in Multiple Sclerosis.

Authors:  Frances K Nally; Chiara De Santi; Claire E McCoy
Journal:  Cells       Date:  2019-06-05       Impact factor: 6.600

8.  Emerging safety issues in alemtuzumab-treated MS patients.

Authors:  Joep Killestein; Bob van Oosten
Journal:  Mult Scler       Date:  2019-08       Impact factor: 6.312

9.  Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.

Authors:  Trygve Holmøy; Børre Fevang; David Benee Olsen; Olav Spigset; Lars Bø
Journal:  BMC Res Notes       Date:  2019-08-12

10.  The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies.

Authors:  David Baker; Liaqat Ali; Gauri Saxena; Gareth Pryce; Meleri Jones; Klaus Schmierer; Gavin Giovannoni; Sharmilee Gnanapavan; Kathleen C Munger; Lawrence Samkoff; Andrew Goodman; Angray S Kang
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.